The estimated Net Worth of John T Curnutte is at least $1.35 Milione dollars as of 31 August 2018. John Curnutte owns over 17,500 units of Pliant Therapeutics stock worth over $1,349,630 and over the last 11 years John sold PLRX stock worth over $0.
Sign up
John Curnutte PLRX stock SEC Form 4 insiders trading
John has made over 17 trades of the Pliant Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently John exercised 17,500 units of PLRX stock worth $214,550 on 31 August 2018.
The largest trade John's ever made was exercising 60,000 units of Pliant Therapeutics stock on 26 June 2017 worth over $510,000. On average, John trades about 6,071 units every 36 days since 2014. As of 31 August 2018 John still owns at least 110,084 units of Pliant Therapeutics stock.
You can see the complete history of John Curnutte stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's John Curnutte's mailing address?
John's mailing address filed with the SEC is C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Pliant Therapeutics
Over the last 4 years, insiders at Pliant Therapeutics have traded over $16,925,448 worth of Pliant Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Rock Ventures Iii, L.P.Thir... e Thomas A Mccourt. On average, Pliant Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $221,612. The most recent stock trade was executed by Eric Lefebvre on 10 July 2024, trading 12,319 units of PLRX stock currently worth $142,408.
What does Pliant Therapeutics do?
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
What does Pliant Therapeutics's logo look like?
Complete history of John Curnutte stock trades at Portola Pharmaceuticals, Orchard Therapeutics plc e Pliant Therapeutics
Pliant Therapeutics executives and stock owners
Pliant Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D.,
Pres, CEO & Director -
Dr. Éric Lefebvre M.D.,
Chief Medical Officer -
Dr. Ãric Lefebvre M.D.,
Chief Medical Officer -
Johannes P. Hull,
Chief Bus. Officer -
Christopher S. Keenan,
VP of Investor Relations & Corp. Communications -
Craig D. Muir,
Interim Chief Technology Officer -
Dr. Keith Lamont Cummings M.B.A., M.D.,
Chief Financial Officer -
Hal Chapman M.D.,
Scientific Founder & Member of Scientific Advisory Board -
Bill DeGrado Ph.D.,
Scientific Founder & Member of Scientific Advisory Board -
Dean Sheppard M.D.,
Scientific Founder & Member of Scientific Advisory Board -
Dr. Rik Derynck,
Scientific Founder & Member of Scientific Advisory Board -
Katharine Knobil,
Director -
Rock Ventures Iii, L.P.Thir...,
-
Hans Hull,
Chief Business Officer -
Steve E. Krognes,
Director -
Darren S Cline,
Director -
Thomas A Mccourt,
Director -
Group, Llc Green Jeremy Red...,
-
Hoyoung Huh,
Director -
Neil Exter,
Director -
Barbara Howes,
Chief Human Resource Officer -
Rock Ventures Iii, L.P.Thir...,
-
David E I Pyott,
Director -
Gayle A Crowell,
Director -
John T Curnutte,
Director -
Charles J Homcy,
Director -
Suzanne Louise Bruhn,
Director -
Smital Shah,
Director -
Bernard Coulie,
President and CEO -
Mike Ouimette,
General Counsel & Corp. Sec'y -
Keith Lamont Cummings,
Chief Financial Officer -
Eric Lefebvre,
Chief Medical Officer -
Lily Cheung,
Chief Human Resource Officer